Open

ARGX-113-2308

To determine how well efgartigimod IV compared to placebo works in participants with AChR-Ab seronegative General Myasthyenia Gravis

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

Questions updating how their Myasthenia Gravis is doing; Any new adverse events, any changes in medication, any hospital visits. We will also complete Myasthenia Muscle testing, patient will complete a set of questionnaire, Safety blood draw, Urinlaysis, ECG

Incentives

reimbursement for gas and mileage

In-person visits:
22

Phone or online visits:
9

Total length of participation:
117 weeks

Looking for Specific Volunteers

Able to participate:

Myasthenia Gravis

Not eligible if:

Any other autoimmune condition
ongoing active malignancy

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

James Howard
Neurology

Study Type

Clinical or Medical
Interventional

Study Topics

Brain, Head, Nervous System

IRB Number

24-0891

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.